Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H (02335.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 7.99B

MomentumView details →

1D Return

+0.07%

YTD Return

—

RSI (14)

40.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 7.99B

RSI (14)

40.7

MomentumView details →

1D Return

+0.07%

YTD Return

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Mackyo Pharmaceuticals announced the completion of Phase II clinical trials for its self-developed candidate drug MT200605, which treats acute ischemic stroke, demonstrating significant efficacy and good safety.9d ago

Micot Medical announced that research results for its main product XTL6001 were accepted for presentation at multiple top international academic conferences in diabetes, metabolic diseases, and kidney diseases, including EASD 2026 and ASN Kidney Week 2026.18d ago

Similar companies

Spyre Therapeutics, Inc.SYRE Immunovant, Inc.IMVT Alkermes plcALKS CARsgen Therapeutics Holdings Limited02171.HK Lepu Biopharma Co., Ltd.02157.HK Belite Bio, IncBLTE Find similar companies →

Latest newsMore news →

Mackyo Pharmaceuticals announced the completion of Phase II clinical trials for its self-developed candidate drug MT200605, which treats acute ischemic stroke, demonstrating significant efficacy and good safety.9d ago Micot Medical announced that research results for its main product XTL6001 were accepted for presentation at multiple top international academic conferences in diabetes, metabolic diseases, and kidney diseases, including EASD 2026 and ASN Kidney Week 2026.18d ago